CD8A and neoplasm: As shown in Figure 4C, the mice treated with the vaccine and aPDL1 resulted in the higher percentage of tumor infiltrating CD8+ T cell (22.7%) than those only treated with the vaccine (7.33%), demonstrating that the combination of the vaccine and aPDL1 could efficiently activate the immune system for enhanced tumor inhibition.